GW4869 has demonstrated potential in inhibiting processes like the epithelial–mesenchymal transition in non-small-cell lung cancer (NSCLC), particularly in those cases with EGFR mutations [156]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.